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Background: Since the original characterizations of the pathological features defining glomerulonephritis in
systemic lupus erythematosus (SLE) were reported, numerous studies have linked the development of pathology to
the abnormal expression of protein in urine. The determination of proteinuria is important and necessary; however,
this alone is not predictive enough to confirm a suspected diagnosis, especially in an early state of disease when
symptoms are not yet observed. Furthermore, several studies have already highlighted the pitfalls of proteinuria
both as a clinical prognostic marker and as a factor predicting the progressive loss of renal function. Therefore, the
identification of more accurate and predictive biomarkers is urgently needed. To address this, comparative urinary
and kidney profiling was performed in the MRL-lpr/lpr mouse as a model of lupus tubulointerstitial nephritis and
lupus glomerulonephritis corresponding to SLE in humans.
Results: Tamm-Horsfall glycoprotein (THG; uromodulin) and beta2-microglubulin (β2M) were identified as immune
process-related molecules in the urine and kidney of the MRL-lpr/lpr mouse model. Furthermore, we show that the
combinatory expression profile of THG and β2M as biomarkers, normalized by the proteinuria level, is more predictive
than proteinuria determination alone. Data were confirmed by comparative urinary profiling of SLE in mice by Western
blot and quantitative polymerase chain reaction (qPCR) analysis.
Conclusion: Based on our results, we are able to diagnose SLE in the MRL-lpr/lpr mouse in a very early state of
disease, when the proteinuria level alone is not able to confirm a suspected diagnosis. The pre-validation of our
urinary biomarkers is associated with clinical outcomes of glomerulonephritis in humans and merits additional
investigation. Further conformations of our predictive biomarkers in the urine of SLE patients in the course of a
clinical study are still ongoing.
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Systemic lupus erythematosus (SLE) is a chronic, inflamma-
tory, systemic autoimmune disease in humans of unknown
origin. It is a multisystem disease characterized by a strong
female predilection, a diversity of autoantibodies of which
those against nuclear antigens typically predominate,
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unless otherwise stated.cell and complement activation and leucocyte emigration
and activation [1]. It has a prevalence of between 2 and
7.6 cases per 100,000 individuals [2], depending on ethni-
city, and causes significant morbidity and increased mortal-
ity, particularly for patients with renal or central nervous
system involvement [3]. The immunopathology of lupus
is considered to result from loss of peripheral tolerance,
production of autoantibodies and subsequent autoantibody-
mediated tissue destruction. Lupus nephritis (LN), which
occurs in up to two thirds of patients with SLE at some
stage of their illness [4], is believed to result mostly fromal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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[5], which in turn triggers an acute inflammatory response
characterized by activation of infiltrating leucocytes and
renal parenchymal cells. This activation is accompanied
by the production of cytokines and growth factors. End-
stage renal disease (ESRD) is preceded by a chronic phase
with excessive deposition of collagen and other extracellu-
lar matrix macromolecules [6]. The etiology of this disease
is still unknown, but evidence supports a strong genetic
predisposition as well as a role for stochastic and environ-
mental factors.
The diagnosis of SLE is made based on the presence of
4 of 11 criteria set out by the American College of
Rheumatology (ACR). These include kidney biopsy and
function tests, e.g. proteinuria. Kidney biopsy is essential
for LN diagnosis, but this is clearly not a simple procedure
and is associated with an inherent risk. Some of the
routine laboratory parameters such as urinary sediments,
serum level of DNA-anti-DNA immune complexes, and
complements are also helpful in determining the activity
of LN [7-9]. However, sampling is not simple due to inva-
sive procedures and the frequent need for repeat sampling
to confirm initial values. Besides, fluctuations of these
parameters frequently occur during the development of
glomerular as well as tubulointerstitial pathology. The
diagnosis of LN and other kidney-specific diseases is
therefore often made at a late state of disease, when first
symptoms are observed and medication is already required.
Furthermore, there is an urgent need to identify better
predictive markers for kidney function that are more
sensitive or more reliable than the markers currently
used. A robust and alternative determination of the amount
of immune process-related biomarkers in urine would thus
be an effective alternative way to evaluate the severity of
renal inflammation in LN. Following the recommendations
of the EPMA white paper [10,11] on developing integrative
medical approaches, our predictive panels of biomarkers in
the urine of SLE patients in the course of a clinical study
are still ongoing and data will be published in an upcoming
EPMA Journal.
Methods
Scientific rational for using MRL-lpr/lpr mice as a model
of human SLE
Several animal models, manifesting phenotypes observed
in SLE, have been identified in nature or generated in the
laboratory. These models generally present physiological
alterations observed in human patients and can be used as
important tools for genetic, clinical and histopathological
studies for lupus tubulointerstitial nephritis and lupus
glomerulonephritis. The MRL-lpr/lpr mouse model is
the most widely used animal model for tubulointerstitial
nephritis and lupus glomerulonephritis corresponding
to SLE in humans. It is a good genetic and biochemicalmodel characterized by glomerular immune complex de-
posits and proliferative glomerulonephritis, progressing to
glomerulosclerosis and kidney failure, and is therefore a
well-accepted mouse model for clinical trials of LN.
The animals were maintained conventionally under
standard conditions (22°C ± 1°C, 55% ± 5% relative hu-
midity, 10 changes of fresh air, 12:12-h day/night cycle)
in groups in type III Makrolon® cages with sawdust bed-
ding (Bayer MaterialScience LLC, Sheffield, MA, USA).
Standard laboratory chow (SNIFF® R/M-H diet for mice
and rats, Research Diets, Uden, The Netherlands) and
drinking water from the municipal supply were given ad
libitum. Mice were housed in groups during the treatment
period.
Statement on animal welfare
Studies described in this report were performed according
to a notification (§9, Österreichisches Tierversuchsgesetz)
approved by the governmental authority (Landesregierung
Wien, Magistratsabteilung 58).
Animal experimental conditions
Mice were divided into three groups of mice weighing
between 25 and 35 g. The treatment started at 10 weeks
of age and continued daily for 9 weeks. Groups received
vehicle control or cyclophosphamide (Sigma C-0768, St.
Louis, MO, USA). The treatment schedule is described in
Table 1. The CpG oligo-ODN 1668 5′ TCG ATG ACG
TTC CTG ATG CT 3′ was used as a disease accelerator.
Disease monitoring
MRL-lpr/lpr mice were monitored weekly throughout
their disease course for body weight and proteinuria. If
they became moribund, mice were sacrificed by cervical
dislocation. Moribund animals usually demonstrated
signs of severe nephritis, such as persistent proteinuria
and body weight loss. At sacrifice, the kidney was excised
and fixed. Proteinuria and kidney histopathology severity
scores were determined using the protocols described
below.
Evaluation of kidney disease
Proteinuria
Twenty-four-hour urine samples were collected from each
animal at regular intervals from 10 weeks of age until the
end of the experiment. Urine protein levels were scored.
For proteinuria determination, two different assay methods
were selected and performed according to the manufac-
turer's protocol: the BCA protein assay (Pierce, Cat. No.
23227, Thermo Fisher Scientific, Waltham, MA, USA) and
the Bradford assay (Bio-Rad, Cat. No. 500-0006, Bio-Rad
Laboratories, Hercules, CA, USA) [13]. Based on the higher
stability and enhanced reproduction of the results, the
Bradford assay was commonly used.
Table 1 THG oligonucleotide primers and probes
Group Strain Treatment Dose Route Concentration at delivery (mg/ml) Delivery volume
1 MRL-lpr/lpr Vehicle bid p.o. - 10 μl/g
2 MRL-lpr/lpr Cyclophosphamide 35 (mg/kg/week) i.p. 5 7 μl/g
3 MRL-lpr/lpr CpG-ODN 40 μg on alternate days i.p. - 100 μl
According to [12].
Boenisch et al. The EPMA Journal 2014, 5:5 Page 3 of 11
http://www.epmajournal.com/content/5/1/5Kidney histopathology
Kidney sections from Bouin's solution-fixed (HT10-1-32,
Sigma, Vienna, Austria) paraffin-embedded material were
stained in periodic acid-Schiff (PAS) reagent (Cat # 21-
1308021C, Bio-Optica, Milan, Italy). Histologic exam-
ination of sections was carried out in a blind manner,
and the severity of kidney disease was defined using
the activity/chronicity index according to [14]. Table 2
outlines the specific histologic features of this renal
pathology semi-quantitative scoring system. Composite
scores derived from the sum of scores for individual active
lesions (activity index) and chronic, irreversible lesions
(chronicity index) were calculated. Two active lesions,
fibrinoid necrosis and cellular crescents, were each arbi-
trarily weighted by a factor of 2 on the assumption that
these features are disproportionately more ominous than
the other active lesions.
Proteomics procedure
Urine collection
In proteomics, urine collection tubes should always in-
clude an appropriate amount and composition of prote-
ase inhibitors to avoid protein degradation. After urine
collection, delays in analyzing the samples can result in
artefacts, and thus, it is important to handle the samples
quickly. Note that if a sample cannot be analyzed imme-
diately, it should be frozen (−80°C). The time interval
between collection and analysis should be as short as
possible. A delay in this handling step could have a high
impact on the urine status and protein pattern. Changes
that can occur with time after collection include protein
degradation caused by proteases in urine, decreased clarityTable 2 A/C scoring criteria
Activity index Chronicity index
Glomerular
abnormalities
Cellular proliferation Glomerular sclerosis
Fibrinoid necrosis, karyorrhexisa Fibrous crescent
Cellular crescentsa




Mononuclear cell infiltration Interstitial fibrosis
Tubular atrophy
Scoring from 0 to 3, where 0, absent; 1, mild; 2, moderate; 3, severe.
aWeighted by a factor of 2. The maximum score of the activity index is 24, and
that of the chronicity index is 12.due to crystallization of solutes, rising pH, loss of ketone
bodies, loss of bilirubin, cell lysis leading to additional
proteins in samples, and overgrowth of contaminating
microorganisms. For this reason, the main challenges
in working with urine for biomarker discovery are in
the standardization of urine sample collection, storage,
shipment (if necessary), enrichment of potential markers
with low abundances and quantification of the excretion
rate from a single marker. In the course of our project,
mouse urine samples from the whole day were collected
in 0.5-ml tubes including a protease inhibitor cocktail
(cOmplete, Roche Diagnostic, 11 697 498 001, Basel,
Switzerland), immediately frozen at −80°C and kept
frozen until use. Samples were handled and stored as
described [15].
Kidney sample homogenization
Whole kidney tissue samples were suspended in sucrose
buffer consisting 20 mM HEPES (pH 7.5), 320 mM sucrose,
1 mM ethylenediaminetetraacetic acid (EDTA), 5 mM
DTE, 1 protease inhibitor cocktail tablet (Roche Diagnostic,
Art. Nr. 11 697 498 001)/50 ml homogenization buffer,
1 mM phenylmethanesulfonyl fluoride (PMSF), 0.2 mM
Na3VO3 and 1 mM NaF using a glass-Teflon potter as a
homogenizer. After 10 strokes at 4°C, the suspension was
centrifuged at 800 × g for 10 min at 4°C to sediment the
non-suspended material. To receive the fractions enriched
with microsomal, mitochondrial and cytosolic proteins,
the supernatant was further centrifuged at 10,000 × g for
15 min at 4°C and then at 100,000 × g for 1 h at 4°C. The
cell debris of the mitochondrial and microsomal fractions
was suspended in 0.5 ml of a sample buffer consisting of
40 mM Tris, 7 M urea, 2 M thiourea, 4% CHAPS, 10 mM
1,4-dithioerythrol, 1 mM EDTA and a mixture of protease
inhibitor, 1 mM PMSF and 1 protease inhibitor cocktail
tablet (Roche Diagnostic, Art. Nr. 11 697 498 001)/50 ml
homogenization buffer. The supernatant was further cen-
trifuged at 100,000 × g for 1 h to sediment the undissolved
material. The protein content in the supernatant was deter-
mined by a Bradford reaction performed as per the manu-
facturer's protocol. The protein concentration is normally
approximately 8–12 mg/ml for the main fraction.
Electrophoresis
Samples of the mitochondrial, microsomal and cytosolic
fractions were desalted by using membrane filter tubes
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2.0 mg was applied on immobilized pH 3–10 non-linear
gradient strips (Bio-Rad, Hercules, CA, USA) at both
the basic and acidic ends of the strips. The proteins
were focused at 200 V, after which the voltage was
gradually increased to 3,000 V with 3 V/min. Focusing
was continued at 3,000 V for additional 12 h. The second-
dimension separation was performed on 12% non-linear
gradient, polyacrylamide gels (Serva, Heidelberg, Germany,
and other reagents for the polyacrylamide gel preparation
from Bio-Rad, Hercules, CA, USA).
Staining and destaining
After protein fixing with 50% (v/v) methanol containing
5% (v/v) phosphoric acid for 12 h, the gels were stained
with colloidal Coomassie blue (Novex, San Diego, CA,
USA) for further 24 h. The gels were destained with water
and scanned in a Molecular Dynamics Personal densi-
tometer (Amersham Pharmacia Biotechnology, Amersham,
UK). The images were processed using Photoshop (Adobe)
and PowerPoint (Microsoft) software. Protein spots
were quantified using the ImageMaster 2D Elite software
(Amersham Pharmacia Biotechnology).
Identification of the proteins by PepMap ESI-MS
Electrospray ionization mass spectrometry (ESI-MS) ana-
lysis was performed as described [16] with minor modifi-
cations. Briefly, spots were excised, destained with 30%
(v/v) acetonitrile in 0.1 M ammonium bicarbonate and
dried in a SpeedVac evaporator (Thermo Savant, Inc.,
Holbrook, NY, USA). The dried gel pieces were reswollen
with 5 μl of 3 mM Tris-HCl (pH 8.8) containing 50 ng
trypsin (Promega, Madison, WI, USA), centrifuged for
1 min and left at room temperature for about 12 h.
After digestion, 5 μl of water was added, followed 10 min
later by 4 μl 50% acetonitrile, containing 0.3% trifluoroace-
tic acid, centrifuged for 1 min, and the content was vor-
texed for 20 min. Ten microlitres from the separated
liquid was used to perform the ESI-MS. Calibration was
internal to the samples. The peptide masses were matched
with the theoretical peptide masses of all proteins from all
species of the SWISS-Prot database. For protein search,
monoisotopic masses were used and a mass tolerance of ≈
0.0075% was allowed. The protein search was performed
with software which is similar to the Peptident software
on the ExPASy server (http://expasy.hcuge.ch/sprot/pepti-
dent.html).
Validation by Western blot procedure
The protein content of each sample was determined by
the method of Bradford [13]. For Western blot analysis,
equal amounts of protein (15 μg) were separated by electro-
phoresis on a 10% TB gel (NuPAGE, Invitrogen, Life Tech-
nologies, Carlsbad, CA, USA) using XCell II and Westerntransfer using the XCell II blot module, transferred to
a nitrocellulose membrane (Bio-Rad) following the manu-
facturer's guidelines and description. An affinity-purified
polyclonal rabbit antibody, raised against a 105-kDa por-
tion of human Tamm-Horsfall glycoprotein (THG) was
purchased from Abcam (Cambridge, UK). After transfer,
membranes were blocked for 14 h in a phosphate-buffered
saline-Tween 20 (PBS-T) blocking/wash buffer (PBS ad-
justed to pH= 7.5, 5% non-fat dried milk powder and
0.05% Tween 20). After blocking, the membranes were
immunoblotted with polyclonal rabbit anti-THG (1:5,000
(v/v) PBS blocking buffer) for 1 h at 25°C. After 3 ×
15 min of washing with PBS, the bound antibodies were
visualized by HRP-conjugated goat anti-rabbit IgG (Pierce)
secondary antibody (1:10,000 (v/v) PBS blocking buffer),
and after further 3 × 15 min of washing, by a chemilumin-
escence detection method (Pierce). Exposed and devel-
oped films (Pierce) were scanned, and internal densities of
THG and THG-immune reactive bands were calculated
by the ImageMasterII software program (GE Healthcare,
Little Chalfont, UK).Genomics procedure
RNA preparation
Whole kidney samples were homogenized by using a
bead-based homogenizer (Precellys 24, Bertin Technologies,
Montigny-le-Bretonneux, France), which allows the ex-
traction of several samples simultaneously. Each tissue
occupied a separate sterile plastic tube to avoid sample
carry-over and cross-contamination. Homogenization
was completed within 30 s for 5,600 rpm in pre-cooled
tubes. Total RNA was extracted by the TRIzol method
(Invitrogen) with some modification as described in the
classic TRIzol/1-bromo-3-chloropropane/water extraction
protocol [17]. RNA concentration and purity were de-
termined with a spectrophotometer (BioSpectrometer,
Eppendorf, Hamburg, Germany) by calculating the ratio
of optical density at 260 and 280 nm.Validation of THG by RT-qPCR
Primer and probe sequences for THG (forward primer:
CCCTGAGTGCAATCTGGCTTA, reverse primer: GCAA
TCTTCATCTACCCTGCATT, probe: TGCACCGATCCT
AGTTCCGTGGAGG) were selected using the Primer
Express™ software (Applied Biosystems, Foster City, CA,
USA). To avoid genomic DNA, amplification primers were
located in different exons. Primer and probes for the house-
keeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were obtained from Applied Biosystems as a
ready mix (TaqMan Gene Expression Assay, Order Nr.
4400239).
cDNA synthesis was carried out using the iScript™ cDNA
Synthesis Kit (Bio-Rad) according to the manufacturer's
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of 30 μl.
Using 1 μl cDNA as a template, real-time quantitative
polymerase chain reaction (RT-qPCR) was performed in
a total volume of 20 μl with a final concentration of 400
nM forward/reverse primers and 200 nM TaqMan probe
for THG or 1:20 dilution of GAPDH TaqMan Gene Ex-
pression Assay using the Eppendorf Real Master Kit,
according to the manufacturer's protocol in an Eppendorf
Mastercycler ep realplex gradient S. An initial denatur-
ation for 2 min at 95°C was followed by 40 cycles with
10 s at 95°C and 45 s at 60°C. PCR was performed in a
96-well format (PCR plates, twin.tec, skirted, Eppendorf)
in technical duplicate. Medium CT values were used for
relative quantification compared to the GAPDH gene
according to the formula of the ΔΔCT method [18]. Ex-
pression levels of THG were normalized to the average
of GAPDH.
ELISA procedure for measurement of beta2-microglobulin
according to the EIA method
Preparation of standard rat/mouse beta2-microglobulin
solution
For beta2-microglobulin determination, a corresponding
protein standard from a kit (Mitsubishi Chemical Safety
Institute Ltd., Cat. No. PRH111, Minato-ku, Tokyo, Japan)
was used. For accurate preparation, 2.0 ml of distilled
or deionized water was added into the vial containing
the standard rat beta2-microglubulin (β2M; Catalogue
Nr. PRH111, Mitsubishi Chemical Safety Institute Ltd.),
providing a concentration of 20 ng/ml. Serial dilutions
were prepared to produce standard concentrations of
10, 5, 2.5, 1.25, 0.63 and 0.31 ng/ml. For 0 ng/ml, the
sample diluent buffer was used.
Preparation of test samples
Samples from mouse urine were collected in the presence
of a protease inhibitor (cOmplete, Roche Diagnostic). The
pH values of the test samples were adjusted to 6.5–8.0, since
β2M is completely denatured in 2 h when the pH is 4.0 and
the temperature is 37°C. When kept stored at 4°C, for ex-
ample, when β2M is measured in serum [15], the urine sam-
ple can remain stable for 1 week. If stored below −20°C, it
will remain stable for 12 months. To avoid high background
and interference from the urine, the samples were diluted
into more than 150-fold volume. As the content of β2M in
urine is expected to be in the order of micrograms in 1 ml
of urine, the test samples were diluted whenever deemed
necessary, e.g. 2 ml of the sample diluent buffer was added
into 10 μl of urine to dilute it into 201-fold volume.
Statistics
Results were expressed as means ± standard deviation
(SD). Between-group differences were investigated bythe non-parametric Mann-Whitney U test. Within-group
correlations were done with the non-parametric Spearman
rank correlation coefficient procedure. The level of sig-
nificance was set at P ≤ 0.05. All analyses were run in
duplicate.
Results
Detection of THG protein in urine by proteomics
Characterization of the MRL-lpr/lpr urine proteome by
depletion of impurities by protein precipitation in
combination with 2DE
In urinary proteome analysis, control samples are usually
diluted and require additional processes in order to yield
enough proteins for further investigation. The application
of two-dimensional gel electrophoresis (2DE) to urine re-
quires further steps in sample preparation, including the
concentration and isolation of the proteins. Specifically,
high concentrations of salts, metabolic wastes, lipids and
some small molecules decrease the quality of the 2D gel
and must be removed before analysis. Several protocols
were developed to overcome these problems and to im-
prove the quality of the urine 2D maps. In our case, we
used protein precipitation because it is the most common
method to remove contaminants or interfering substances
from urine samples. It provides a simple, rapid and highly
economic method for concentrating urine of low to
intermediate protein content (0.02–0.50 g/l) prior to
2DE analysis. In the first step, proteins were separated
by 2DE according to their masses and isoelectric points
using pH 3–10 NL IPG strips followed by 12% SDS gels.
The gels were stained with colloidal Coomassie blue. The
main spot in Figure 1 was excised, after in-gel enzymatic
digestion. The tryptic products of the main spot were fur-
ther analyzed by ESI-MS resulting in the mass fingerprint
as shown in Figure 2. The identification was performed by
databank search, and the main spot at 95 kDa was mainly
identified as THG. Besides THG, the most frequently
observed peptides from the main spot were proteolytic
products of haemoglobin, including multiple fragments
from both the α and β subunits. The existence of these
fragments is to be expected as microhematuria, a character-
istic finding in lupus nephritis [6] and vasculitis [14].
A single ESI-MS spectrum is shown in Figure 2A. The
peak at m/z of 572.287 was selected for further MS/MS
analysis. The spectrum obtained was matched to the se-
quence from uromodulin (Mus musculus). Only the y ions
for PMF identification are labelled for simplicity.
Confirmation of THG expression by Western blot
By comparison of the 2DE-PAGE urinary protein pattern,
THG was mainly identified as an upregulated spot in the
vehicle- and CpG-treated mice. Images indicate that THG
is a useful and good biomarker, which was further con-












Figure 1 Proteome identification of Tamm-Horsfall glycoprotein (THG) as a biomarker by 2DE-PAGE of mouse urine.
A
B
NGPCGTVLR, M+H = 1,143.59
(THG , M. musculus)
Figure 2 Identification of THG by peptide fingerprint MS spectra for the THG (uromodulin) peptide NGPCGTVLR. A single ESI-MS
spectrum is shown (A), with the relative quantitation of the protein in the heavy- and light-labelled mixtures obtained by comparing the peak in-
tensities of monoisotopic peaks at m/z of 576.811 and 572.287, respectively. The peak at m/z of 572,287 was select for further MS/MS analysis in
the linear modus of the ESI-MS/MS (B). The spectrum obtained was matched to the sequence of NGPCGTVLR-12C9-cICAT from uromodulin (M.
musculus). Only the y ions are labelled for simplicity.
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control mice and was not detectable in any other organs
(data are not shown), indicating the organ specificity
of anti-THGAb. Compared to the MRL-lpr/lpr mice, a
positive correlation of THG level in the kidney with
increased severity of the disease was observed as shown in
Figure 3.
THG was detected only in the urine samples of healthy
mice and was almost absent in the urine of diseased
MRL-lpr/lpr mice (Figure 3A) while being detectable
in the kidney samples of diseased MRL-lpr/lpr mice
(Figure 3B). Furthermore, we found a positive correlation
of THG levels in the kidneys and a negative correlation of
THG levels in the urine with disease level as determined,
e.g. by proteinuria.
The ratio of THG levels in the kidney vs. THG levels in
the urine of MRL-lpr/lpr mice treated with cyclophospha-












































































Figure 3 THG levels in MRL-lpr/lpr mouse urine and kidney
samples taken at different time points. THG levels in (A) MRL-
lpr/lpr mouse urine and (B) kidney samples taken at different time
points. THG was detected only in the urine samples of healthy
mice and was almost absent in the urine of diseased MRL-lpr/lpr
mice. Furthermore, we found a positive correlation of THG levels
in the kidneys and a negative correlation of THG levels in the
urine with disease level. The reduction of urinary THG is
particularly intriguing.vehicle- or CpG-treated mice (Figure 4). The mean value
in each group is shown by a horizontal line.
THG mRNA expression in kidney tissue
Real-time PCR was performed on cDNA from mRNA
isolated from whole kidney homogenates of two healthy
control mice with a proteinuria level less than 50 mg/dl
and two SLE diseased MRL-lpr/lpr mice with a protein-
uria level higher than 100 mg/dl. Changes in mRNA ex-
pression of THG from 8- to 19-week-old mice, treated
with vehicle, were determined as described in the ‘Genom-
ics procedure’ section. mRNA levels were determined after
normalization for GAPDH and are relative to expression
in healthy control mice (Figure 5A). Although diseased
mice show a slightly higher THG mRNA expression
than healthy mice, this difference was not significant.
Contrary to the urinary THG protein levels in the
vehicle-treated mice (Figure 3), no correlation of THG
mRNA levels with age or proteinuria levels can be de-
tected (Figure 5B). These results indicate that mRNA
expression does not always correlate directly with changes
in protein expression/secretion. The lesser degree of
changes in THG mRNA levels than in THG urinary
protein may indicate complement-dependent changes
in protein expression as a result primarily of inhibition
of THG secretion into the urine. Figure 5A is represen-
tative of two mice per group obtained with an identical
LN score.
Comparison of beta2-microglobulin, THG and protein-
uria as disease markers
THG, beta2-microglobulin and proteinuria levels were
determined at different time points in urine samples of
MRL-lpr/lpr mice treated with cyclophosphamide, CpG
or vehicle (Figure 6). Results show the mean ± SD in
each treatment group. The CpG-treated mice had a sig-
nificantly higher THG level in urine than the correspond-
ing cyclophosphamide- or vehicle-treated mice towards
the end of the treatment. The level of beta2-microglobulin
increased significantly with time in mice treated with CpG
or vehicle, but not in mice treated with cyclophosphamide.
For over 20 years, cyclophosphamide, as an immunosup-
pressive agent, has been the ‘gold standard’ for the treat-
ment of lupus nephritis. The side effects of this agent are
infertility, malignancy, hemorrhagic cystitis and infection,
and therefore, other immunosuppressive agents, such as
CpG, are preferred for maintaining remission, because of
their greater safety.
Predictive potential of beta2-microglobulin
Beta2-microglobulin in urinary mouse samples treated
with vehicle, CpG and cyclophosphamide was determined
at week 11 (Figure 7A) and at the end of the treatment
(Figure 7B). A threshold of 0.1 ng/ml β2M in urine was
selected for prediction of nephritis. For each group, urine
samples were collected from mice with the highest renal
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Figure 4 Ratio of THG levels in the kidney vs. urine of MRL-lpr/lpr mice after treatment. The ratio of the THG levels in the kidney and
urine correlates with disease severity as determined by proteinuria in MRL-lpr/lpr mice (A). The ratio of THG levels in the kidney and urine is sig-
nificantly reduced in the MRL-lpr/lpr mice protected from SLE by treatment with cyclophosphamide, while the vehicle- or CpG-treated mice show
higher THG ratios (B).
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10 subjects identified at week 11 with a significantly
higher level of β2M in urine at the beginning of the
treatment which develop nephritis at weeks 18–20. This
is a probability of 70% compared to a prediction rate of
only 10% by measurement of the proteinuria level alone
(Table 3). The THG excretion in the urine of these mice
was significantly lower than that of the other mice without
nephritis. As shown in Figure 7B, the urinary β2M in mice
at the end of the treatment was much higher than that in
normal controls.
Conclusions
Since the 1970s, a variety of experimental techniques
have been employed to identify urinary biomarkers of
renal injury or kidney failure. While these approaches
have met with some success, modern proteomic tools,
such as MALDI, SELDI, LC-MS/MS, and MudPIT, nowFigure 5 Relative mRNA expression of THG in MRL-lpr/lpr mice kidne
from the vehicle-treated mice classified healthy or SLE-diseased based on t
mRNA and calculated in relation to the relative expression of healthy anim
identical LN score. THG mRNA was detected in kidney samples of the vehic
proteinuria (B).permit broad-based high-throughput analysis of the
urinary proteome. Using the 2DE-PAGE approach in
combination with ESI-MS, comparative urinary and kidney
protein profiling was performed in a MRL-lpr/lpr mouse
model of membranoproliferative glomerulonephritis. Paired
kidney samples were analyzed at a late stage of LN disease
with a high proteinuria level and healthy control mice.
As a result, distinct urinary proteins were identified, of
which several were differently expressed in the kidneys of
the MRL-lpr/lpr mice. Most differently expressed proteins
were identified and further confirmed by Western blot,
enzyme-linked immunosorbent assay (ELISA) and RT-
qPCR in kidney and urine samples. Two identified pro-
teins were markedly altered in the kidney as well as in the
urine compared to the healthy controls with a proteinuria
level as low as 50 mg/dl: Tamm-Horsfall glycoprotein
(THG) (4-fold lower in the urine) and β2M (3-fold
higher in the urine). Western blots demonstrated a markedys. THG and GAPDH mRNA were determined in kidney homogenates
he proteinuria level. THG mRNA expression was normalized to GAPDH
als (A). Results are representative of two animals in each group with an









































































































































































































Figure 6 THG, beta2-microgloblin and proteinuria levels in the urine of MRL-lpr/lpr mice at different time points. THG, beta2-
microglobulin and proteinuria levels were detected in the urine of MRL-lpr/lpr mice treated with cyclophosphamide, CpG or vehicle at different
time points. Results show the mean ± SD in each treatment group.
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Figure 7 Beta2-microglobulin in urinary mouse samples at week 11 (A) and after the treatment (B).
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Table 3 Overview of ELISA results from the
beta2-microglobulin determination
Week Disease state predicted









End of treatment 100 100
aThreshold of β2M in urine = 0.1 ng/ml and that of proteinuria level = 1 mg/ml.
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THG expression in the urine of the MRL-lpr/lpr mice,
which correlated with the severity of disease. These findings
may be related to early complement-dependent alterations
in tubular protein expression which may play critical roles
in the development of tubulointerstitial disease and provide
experimental support for the use of urinary proteomic
profiling of renal injury and/or kidney failure.
Beta2-microglobulin
Results from the 2DE-PAGE experiments on the kidney
from MRL-lpr/lpr mice at the late stage of disease suggest
that measurements of β2M in urine may represent a
quantitative and predictive biomarker of in vivo polyclonal
B cell activation. Our findings showed that an increase
in urinary β2M occurred in MRL-lpr/lpr mice during
intervals that in most cases preceded (70%–90%) 4–8 weeks,
i.e. before the first symptomatic signs of nephritis (pro-
teinuria) were visible. These results suggest that a sizeable
lead time may exist before the occurrence of immuno-
pathologic tissue damage in the kidney. In the course
of the study, the measurement of urinary β2M was
accomplished by a direct method using a solid-phase
nanogram-sensitive ELISA assay that directly measures
rat/mouse β2M in urine. As a control for the assessment
of renal tubular function and the excretion of high mo-
lecular weight proteins in urine, long-term measurements
of THG and proteinuria level were made by using WB
and the Bradford technique, respectively, and compared
with the β2M level. In addition to our findings, we assumed
that longitudinal levels of urinary β2M may be used
to track or monitor the in vivo immunopathologic B
cell activity and may be helpful in predicting a disease
relapse in human SLE patients.
THG
Our results suggest that the urinary excretion of THG,
together with β2M, is a good indicator of the severity of
renal inflammation and has therapeutic implications in
monitoring the disease activity in mice with SLE. Because
β2M is a potent amplifier of acute inflammation [19] andis rarely found in normal urine (as shown in Figure 7A),
we measured this molecule in urine as an indicator of
renal inflammation. Also, previous investigations [20]
have demonstrated the usefulness of urinary THG and
β2M measurement in lupus nephritis. We determined the
urinary THG, proteinuria and β2M excretion in three
groups of MRL-lpr/lpr mice before and after treatment
with CpG, vehicle and cyclophosphamide. As shown in
Figure 7A,B, the urinary β2M excretion increased only
minimally after treatment in three of the four mice in
each group. For each group of 10 animals, urine samples
from the four mice with the highest renal activity at the
end of the treatment were selected for further β2M deter-
mination. Three of the four mice in each group remained
healthy and never reached a level significantly greater
than 0.12 ng/ml, suggesting that the urinary excretion
of β2M seems to be a good predictive indicator of the
severity of renal inflammation and can have thera-
peutic implications in monitoring the disease activity
in MRL-lpr/lpr mice. On the other hand, the urinary
excretion of THG in mice with a higher proteinuria
level was significantly lower than that in normal or in
cyclophosphamide-treated subjects.
Expert recommendations
In conclusion, the measurement of daily or weekly urinary
THG and β2M excretion is a more practical method
for monitoring the progression of lupus nephritis as
compared with proteinuria or serial kidney biopsy alone
as seen in Figures 6 and 7. β2M and THG can be used as
sensitive indicators reflecting proximal and distal renal
tubular damage in MRL-lpr/lpr mice with SLE or neph-
ritis. The validation of our findings in corresponding
human samples is ongoing and will be reported.
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